The consistency of effect direction, the low heterogeneity in resting mPAP, and the robustness of the PASP signal after sensitivity analysis lend confidence that SGLT2 inhibitors contribute meaningfully to hemodynamic improvement in HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.